Overview: Zhejiang Hisun Pharmaceutical Co., Ltd. is involved in the research, development, production, and sale of biological and generic drugs in China, with a market capitalization of CN¥11.31 ...
Assessing SES AI’s Valuation Following Joint Venture Deal With Hisun to Scale Electrolyte Innovation
SES AI (NYSE:SES) just took a big step forward by signing a term sheet with Hisun New Energy Materials Ltd. Co. for a joint venture to manufacture and supply new electrolyte materials at scale. See ...
China’s Zhejiang Hisun Pharmaceutical has gotten in progressively hotter water with the FDA but its troubles have not kept it from striking deals globally with other drugmakers, including one this ...
HONG KONG – China's Zhejiang Hisun Pharmaceutical Co. Ltd. said results of two key phase III trials for HS-25, a cholesterol absorption inhibitor that targets hyperlipoproteinemia, showed both met the ...
Horizon Discovery announced it has entered into an agreement with Hisun Pharmaceuticals (Hisun) to optimize Horizon’s newly engineered CHO bioproduction cell line for commercial use. Hisun will be ...
Under the terms of the license deal, Hisun gets exclusive right in China and will handle manufacturing as well in return for the Master Cell Bank and related technology from Nascent to pursue the full ...
Zhejiang Hisun Pharmaceutical Co Ltd stock price live, this page displays SS 600267 stock exchange data. View the 600267 premarket stock price ahead of the market session or assess the after hours ...
BEIJING – Biologics developer Hisun Bioray Bio-pharmaceutical Co. Ltd., a subsidiary of Chinese state-owned drugmaker Zhejiang Hisun Pharmaceutical Co. Ltd., received ¥3.8 billion (US$540 million) ...
Zhejiang Hisun Biomaterials Co.Ltd. engages in the research, development, production, and sale of polylactic acid in China. Its products are used in various applications that include 3D printing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results